9 giugno 2020

Dompé farmaceutici S.p.A and the Chinese Academy of Sciences collaborate on in-depth studies of over 50 molecules active against Sars-Cov-2

A biochemical screening and crystallography of the 3CL protein were completed, marking a fundamental step for understanding the functional processes of the coronavirus causing Covid19.

MILAN and SHANGHAI – Dompé farmaceutici S.p.A and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM), started a collaboration in March to speed up research on Covid-19.

Sharing results of the research led to the selection of some molecules (about 50) that could prove useful against the Sars-CoV-2 virus.

The in silico and in vitro tests carried out simultaneously in China and in Italy, aim to select a restricted group of active ingredients, effective to counteract the mechanisms of action - cell replication and entry mechanism in a human cell - of the virus, with a good safety profile and tolerability for humans.

The biochemical screening and crystallography of the Sars-CoV-2 virus 3CL protein provided by the SIMM are proving to be of particular importance to accelerate the research activities in Europe. This protein is in fact the basis of the main functional mechanisms of aggression of the human cell by the virus. A better understanding of the biochemical dynamics of this protein represents one of the fundamental steps to identify effective COVID-19 treatments.

Collaboration continues with an in-depth analysis of laboratory tests with the aim of identifying a mix of active ingredients against the Sars-CoV-2 virus that can be validated with clinical trials.

Dompé Farmaceutici S.p.A. Socio Unico / Capitale sociale € 50.000.000,00
REA MI 289519 - Registro Imprese di Milano / Codice Fiscale e Partita IVA (VAT) IT00791570153